(Q55038495)

16 June 2018

editorial

0 references

title

Immunity and HER2-positive disease: never stop questioning. (English)

1 reference

16 June 2018

author

Sherene Loi

series ordinal

1

1 reference

16 June 2018

publication date

20 October 2015

1 reference

16 June 2018

published in

Annals of Oncology

1 reference

16 June 2018

volume

26

1 reference

16 June 2018

issue

12

1 reference

16 June 2018

page(s)

2361-2362

1 reference

16 June 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV497

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV497

1 reference

16 June 2018

1 reference

16 June 2018